Skip to main content

Advertisement

SpringerLink
Log in

The classification of lymphomas: a new beginning or the end of an era?

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract.

The World Health Organisation Classification of Tumours of the Haematopoietic and Lymphoid Tissues has recently been published. This is the latest in a long line of classifications of haematological malignancies and will be the international standard. It is now possible to achieve high levels of diagnostic accuracy for the main types of lymphoma. However, many of the entities encompass a wide spectrum of clinical outcomes and this approach to classification may be insufficiently precise for the future needs of haematological oncology. Rapid progress in targeted therapies may require further developments in tumour classification based on pathogenic features rather than arbitrary morphological criteria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.

  2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994; 84:1361–1392.

    Google Scholar 

  3. Fisher RI, Miller TP, Grogan TM. New REAL clinical entities. Cancer J Sci Am 1998; 4 Suppl 2:S5–S12.

    Google Scholar 

  4. Weisenburger DD. Nodal marginal zone lymphoma. Am J Surg Pathol 2000; 24:315–317.

    Google Scholar 

  5. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000; 96:410–419.

    Google Scholar 

  6. Dierlamm J, Wlodarska I, Michaux L, et al. Genetic abnormalities in marginal zone B-cell lymphoma. Hematol Oncol 2000; 18:1–13.

    Google Scholar 

  7. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36:115–127.

    Google Scholar 

  8. Gagneten D, Hijazi YM, Jaffe ES, Solomon D. Mantle cell lymphoma: a cytopathological and immunocytochemical study. Diagn Cytopathol 1996; 14:32–37.

    Google Scholar 

  9. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909–3918.

    Google Scholar 

  10. Owen RG, Parapia LA, Higginson J, et al. Clinicopathological correlates of IgM paraproteinemias. Clin Lymphoma 2000; 1:39–43.

    Google Scholar 

  11. Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002; 100:635–639.

    Google Scholar 

  12. Kipps TJ. Genetics of chronic lymphocytic leukaemia. Hematol Cell Ther 2000; 42:5–14.

    Google Scholar 

  13. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840–1847.

    Google Scholar 

  14. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–54.

  15. Starostik P, O'Brien S, Chung CY, et al. The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia. Leuk Res 1999; 23:795–801.

    Google Scholar 

  16. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503–511.

    Google Scholar 

  17. Dohner H, Stilgenbauer S, Fischer K, Bentz M, Lichter P. Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. Leukemia 1997; 11 Suppl 2:S19–S24.

    Google Scholar 

  18. Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 1999; 77:266–281.

    Google Scholar 

  19. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95:802–806.

    Google Scholar 

  20. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95:1950–1956.

    Google Scholar 

  21. Campo E, Miquel R, Krenacs L, Sorbara L, Raffeld M, Jaffe ES. Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol 1999; 23:59–68.

    Google Scholar 

  22. Owen RG, Barrans SL, Richards SJ, et al. Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 2001; 116:420–428.

    Google Scholar 

  23. Yamamoto T, Ohi M, Nishioka K. Lymphomatoid papulosis associated with Sjögren's syndrome. J Dermatol 2002; 29:174–177.

    Google Scholar 

  24. Wotherspoon AC. Gastric lymphoma of mucosa-associated lymphoid tissue and Helicobacter pylori. Annu Rev Med 1998; 49:289–299.

    Google Scholar 

  25. Fischbach W. Gastrointestinal lymphomas: the Würzburg study experience. Recent Results Cancer Res 2000; 156:134–140.

    Google Scholar 

  26. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357:39–40.

    Google Scholar 

  27. Sugiyama T, Asaka M, Nakamura T, Nakamura S, Yonezumi S, Seto M. API2-MALT1 chimeric transcript is a predictive marker for the responsiveness of H. pylori eradication treatment in low-grade gastric MALT lymphoma. Gastroenterology 2001; 120:1884–1885.

    Google Scholar 

  28. Hoeve MA, Gisbertz IA, Schouten HC, et al. Gastric low-grade MALT lymphoma, high-grade MALT lymphoma and diffuse large B cell lymphoma show different frequencies of trisomy. Leukemia 1999; 13:799–807.

    Google Scholar 

  29. Starostik P, Patzner J, Greiner A, et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 2002; 99:3–9.

    Google Scholar 

  30. Calvert RJ, Evans PA, Randerson JA, Jack AS, Morgan GJ, Dixon MF. The significance of B-cell clonality in gastric lymphoid infiltrates. J Pathol 1996; 180:26–32.

    Google Scholar 

  31. Durie DG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1977; 36:842–854.

    Google Scholar 

  32. Salmon SE, Cassady JR. Plasma cell neoplasms. In: DeVita VT, Hellman S, Rosenberg S. eds. Cancer principles and practice of oncology. Philadelphia: Lippincott, p 1854.

  33. Rawstron AC, Fenton JA, Ashcroft J, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000; 96:3880–3886.

    Google Scholar 

  34. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 1997; 97:46–55.

    Google Scholar 

  35. Drach J, Kaufmann H, Urbauer E, Schreiber S, Ackermann J, Huber H. The biology of multiple myeloma. J Cancer Res Clin Oncol 2000; 126:441–447.

    Google Scholar 

  36. Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 2000; 113:831–837.

    Google Scholar 

  37. Ronchetti D, Finelli P, Richelda R, et al. Molecular analysis of 11q13 breakpoints in multiple myeloma. Blood 1999; 93:1330–1337.

    Google Scholar 

  38. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma [published erratum appears in J Clin Oncol 2000; 18:2006]. J Clin Oncol 2000; 18:317–324.

    Google Scholar 

  39. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000;96:3195–9.

    CAS  PubMed  Google Scholar 

  40. Ohshima K, Kawasaki C, Muta H, et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39:156–162.

    Google Scholar 

  41. Akasaka T, Ueda C, Kurata M, et al. Nonimmunoglobulin (non-Ig)/BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6. Blood 2000; 96:2907–2909.

    Google Scholar 

  42. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92:3152–3162.

    Google Scholar 

  43. Pescarmona E, De Sanctis V, Pistilli A, et al. Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas. J Pathol 1997; 183:281–286.

    Google Scholar 

  44. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87:265–272.

    Google Scholar 

  45. Harrison CN, Vaughan G, Devereux S, Linch DC. Outcome of secondary myeloid malignancy in Hodgkin's disease: the BNLI experience. Eur J Haematol 1998; 61:109–112.

    Google Scholar 

  46. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996; 88:1046–1051.

    Google Scholar 

  47. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68–74.

    Google Scholar 

  48. Chaganti SR, Chen W, Parsa N, et al. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer 1998; 23:323–327.

    Google Scholar 

  49. Mohamed AN, Palutke M, Eisenberg L, Al Katib A. Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant. Cancer Genet Cytogenet 2001; 126:45–51.

    Google Scholar 

  50. Stamatopoulos K, Kosmas C, Belessi C, Stavroyianni N, Kyriazopoulos P, Papadaki T. Molecular insights into the immunopathogenesis of follicular lymphoma. Immunol Today 2000; 21:298–305.

    Google Scholar 

  51. Stamatopoulos K, Kosmas C, Belessi C, Stavroyianni N, Kyriazopoulos P, Papadaki T. Molecular insights into the immunopathogenesis of follicular lymphoma. Immunol Today 2000; 21:298–305.

    Google Scholar 

  52. Pinyol M, Cobo F, Bea S, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91:2977–2984.

    Google Scholar 

  53. Hough RE, Goepel JR, Alcock HE, Hancock BW, Lorigan PC, Hammond DW. Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. Br J Cancer 2001; 84:499–503.

    Google Scholar 

  54. Lossos IS, Levy R. Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5' noncoding regulatory region of the BCL-6 gene. Blood 2000; 96:635–639.

    Google Scholar 

  55. Matolcsy A, Warnke RA, Knowles DM. Somatic mutations of the translocated bcl-2 gene are associated with morphologic transformation of follicular lymphoma to diffuse large-cell lymphoma. Ann Oncol 1997; 8 Suppl 2:119–122.

    Google Scholar 

  56. Weisenburger DD, Gascoyne RD, Bierman PJ, et al. Clinical significance of the t(14;18) and BCL2 overexpression in follicular large cell lymphoma. Leuk Lymphoma 2000; 36:513–523.

    Google Scholar 

  57. Knutsen T. Cytogenetic mechanisms in the pathogenesis and progression of follicular lymphoma. Cancer Surv 1997; 30:163–192.

    Google Scholar 

  58. Rodriguez J, McLaughlin P, Hagemeister FB, et al. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 1999; 93:2202–2207.

    Google Scholar 

  59. Cheson BD. CHOP plus rituximab—balancing facts and opinion. N Engl J Med 2002; 346:280–282.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Haematological Malignancy Diagnostic Service, Algernon Firth Building, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds, LS1 3EX, UK

    A. S. Jack

Authors
  1. A. S. Jack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. S. Jack.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jack, A.S. The classification of lymphomas: a new beginning or the end of an era?. Eur J Nucl Med Mol Imaging 30 (Suppl 1), S13–S18 (2003). https://doi.org/10.1007/s00259-003-1155-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1155-8

Keywords

Search

Navigation